Paclitaxel cytotoxicity against human lung cancer cell lines increases with prolonged exposure durations

Mark S. Georgiadis, Edward K. Russell, Adi F. Gazdar, Bruce E. Johnson

Research output: Contribution to journalArticle

60 Citations (Scopus)

Abstract

Paclitaxel blocks cells in G2-M, and this may result in a schedule-dependent effect on paclitaxel cytotoxicity. To test this hypothesis, we evaluated paclitaxel cytotoxicity in 28 human lung cancer cell lines. Fourteen of the cell lines were derived from patients with non-small cell lung cancer (NSCLCL), and 14 were from patients with small cell lung cancer (SCLC). All cell lines were exposed to a range of paclitaxel concentrations for durations of 3, 24, and 120 h, and cytotoxicity was measured with a tetrazolium-based assay. The median IC50 values for all 28 cell lines at exposure durations of 3, 24, and 120 h were >32 μM, 23 μM, and 0.38 μM, respectively. The median IC50 values for the NSCLC cell lines were >32 μM, 9.4 μM, and 0.027 μM at exposure durations of 3, 24 and 120 h, respectively. For the 14 SCLC cell lines, the median IC50 values were >32 μM, 25 μM, and 5.0 μM, respectively. Five of the 14 SCLC cell lines had IC50 values at 120 h of paclitaxel exposure that were 1000-fold less than the remaining SCLC cell lines. The median IC50 values for these five sensitive SCLC cell lines at 3-, 24-, and 120-h exposures were >32 μM, 23 μM, and <0.0032 μM, respectively. These in vitro cytotoxicity results were independent of the paclitaxel diluent, a 1:1 solution of ethanol and Cremophor EL. We conclude that longer durations of paclitaxel exposure result in an increase in the chemosensitivity of some human lung cancer cell lines and that this phenomenon is more consistent within NSCLC cell lines than in SCLC cell lines.

Original languageEnglish (US)
Pages (from-to)449-454
Number of pages6
JournalClinical Cancer Research
Volume3
Issue number3
StatePublished - 1997

Fingerprint

Paclitaxel
Lung Neoplasms
Cell Line
Small Cell Lung Carcinoma
Inhibitory Concentration 50
Non-Small Cell Lung Carcinoma
Appointments and Schedules
Ethanol

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Paclitaxel cytotoxicity against human lung cancer cell lines increases with prolonged exposure durations. / Georgiadis, Mark S.; Russell, Edward K.; Gazdar, Adi F.; Johnson, Bruce E.

In: Clinical Cancer Research, Vol. 3, No. 3, 1997, p. 449-454.

Research output: Contribution to journalArticle

Georgiadis, Mark S. ; Russell, Edward K. ; Gazdar, Adi F. ; Johnson, Bruce E. / Paclitaxel cytotoxicity against human lung cancer cell lines increases with prolonged exposure durations. In: Clinical Cancer Research. 1997 ; Vol. 3, No. 3. pp. 449-454.
@article{252f78cc5a334b84a94d408a2f7d7db8,
title = "Paclitaxel cytotoxicity against human lung cancer cell lines increases with prolonged exposure durations",
abstract = "Paclitaxel blocks cells in G2-M, and this may result in a schedule-dependent effect on paclitaxel cytotoxicity. To test this hypothesis, we evaluated paclitaxel cytotoxicity in 28 human lung cancer cell lines. Fourteen of the cell lines were derived from patients with non-small cell lung cancer (NSCLCL), and 14 were from patients with small cell lung cancer (SCLC). All cell lines were exposed to a range of paclitaxel concentrations for durations of 3, 24, and 120 h, and cytotoxicity was measured with a tetrazolium-based assay. The median IC50 values for all 28 cell lines at exposure durations of 3, 24, and 120 h were >32 μM, 23 μM, and 0.38 μM, respectively. The median IC50 values for the NSCLC cell lines were >32 μM, 9.4 μM, and 0.027 μM at exposure durations of 3, 24 and 120 h, respectively. For the 14 SCLC cell lines, the median IC50 values were >32 μM, 25 μM, and 5.0 μM, respectively. Five of the 14 SCLC cell lines had IC50 values at 120 h of paclitaxel exposure that were 1000-fold less than the remaining SCLC cell lines. The median IC50 values for these five sensitive SCLC cell lines at 3-, 24-, and 120-h exposures were >32 μM, 23 μM, and <0.0032 μM, respectively. These in vitro cytotoxicity results were independent of the paclitaxel diluent, a 1:1 solution of ethanol and Cremophor EL. We conclude that longer durations of paclitaxel exposure result in an increase in the chemosensitivity of some human lung cancer cell lines and that this phenomenon is more consistent within NSCLC cell lines than in SCLC cell lines.",
author = "Georgiadis, {Mark S.} and Russell, {Edward K.} and Gazdar, {Adi F.} and Johnson, {Bruce E.}",
year = "1997",
language = "English (US)",
volume = "3",
pages = "449--454",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "3",

}

TY - JOUR

T1 - Paclitaxel cytotoxicity against human lung cancer cell lines increases with prolonged exposure durations

AU - Georgiadis, Mark S.

AU - Russell, Edward K.

AU - Gazdar, Adi F.

AU - Johnson, Bruce E.

PY - 1997

Y1 - 1997

N2 - Paclitaxel blocks cells in G2-M, and this may result in a schedule-dependent effect on paclitaxel cytotoxicity. To test this hypothesis, we evaluated paclitaxel cytotoxicity in 28 human lung cancer cell lines. Fourteen of the cell lines were derived from patients with non-small cell lung cancer (NSCLCL), and 14 were from patients with small cell lung cancer (SCLC). All cell lines were exposed to a range of paclitaxel concentrations for durations of 3, 24, and 120 h, and cytotoxicity was measured with a tetrazolium-based assay. The median IC50 values for all 28 cell lines at exposure durations of 3, 24, and 120 h were >32 μM, 23 μM, and 0.38 μM, respectively. The median IC50 values for the NSCLC cell lines were >32 μM, 9.4 μM, and 0.027 μM at exposure durations of 3, 24 and 120 h, respectively. For the 14 SCLC cell lines, the median IC50 values were >32 μM, 25 μM, and 5.0 μM, respectively. Five of the 14 SCLC cell lines had IC50 values at 120 h of paclitaxel exposure that were 1000-fold less than the remaining SCLC cell lines. The median IC50 values for these five sensitive SCLC cell lines at 3-, 24-, and 120-h exposures were >32 μM, 23 μM, and <0.0032 μM, respectively. These in vitro cytotoxicity results were independent of the paclitaxel diluent, a 1:1 solution of ethanol and Cremophor EL. We conclude that longer durations of paclitaxel exposure result in an increase in the chemosensitivity of some human lung cancer cell lines and that this phenomenon is more consistent within NSCLC cell lines than in SCLC cell lines.

AB - Paclitaxel blocks cells in G2-M, and this may result in a schedule-dependent effect on paclitaxel cytotoxicity. To test this hypothesis, we evaluated paclitaxel cytotoxicity in 28 human lung cancer cell lines. Fourteen of the cell lines were derived from patients with non-small cell lung cancer (NSCLCL), and 14 were from patients with small cell lung cancer (SCLC). All cell lines were exposed to a range of paclitaxel concentrations for durations of 3, 24, and 120 h, and cytotoxicity was measured with a tetrazolium-based assay. The median IC50 values for all 28 cell lines at exposure durations of 3, 24, and 120 h were >32 μM, 23 μM, and 0.38 μM, respectively. The median IC50 values for the NSCLC cell lines were >32 μM, 9.4 μM, and 0.027 μM at exposure durations of 3, 24 and 120 h, respectively. For the 14 SCLC cell lines, the median IC50 values were >32 μM, 25 μM, and 5.0 μM, respectively. Five of the 14 SCLC cell lines had IC50 values at 120 h of paclitaxel exposure that were 1000-fold less than the remaining SCLC cell lines. The median IC50 values for these five sensitive SCLC cell lines at 3-, 24-, and 120-h exposures were >32 μM, 23 μM, and <0.0032 μM, respectively. These in vitro cytotoxicity results were independent of the paclitaxel diluent, a 1:1 solution of ethanol and Cremophor EL. We conclude that longer durations of paclitaxel exposure result in an increase in the chemosensitivity of some human lung cancer cell lines and that this phenomenon is more consistent within NSCLC cell lines than in SCLC cell lines.

UR - http://www.scopus.com/inward/record.url?scp=0030889417&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030889417&partnerID=8YFLogxK

M3 - Article

VL - 3

SP - 449

EP - 454

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 3

ER -